Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $105.8 million.

  • Akebia Therapeutics' Non-Current Assets fell 112.69% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $430.0 million, marking a year-over-year decrease of 470.12%. This contributed to the annual value of $106.8 million for FY2024, which is 1352.85% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Non-Current Assets of $105.8 million as of Q3 2025, which was down 112.69% from $110.9 million recorded in Q2 2025.
  • Akebia Therapeutics' Non-Current Assets' 5-year high stood at $280.8 million during Q2 2021, with a 5-year trough of $105.8 million in Q3 2025.
  • In the last 5 years, Akebia Therapeutics' Non-Current Assets had a median value of $135.3 million in 2023 and averaged $168.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 4100.5% in 2021, then surged by 262.63% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Non-Current Assets (Quarter) stood at $258.2 million in 2021, then crashed by 33.82% to $170.9 million in 2022, then dropped by 27.69% to $123.6 million in 2023, then fell by 13.53% to $106.8 million in 2024, then decreased by 0.96% to $105.8 million in 2025.
  • Its Non-Current Assets stands at $105.8 million for Q3 2025, versus $110.9 million for Q2 2025 and $106.4 million for Q1 2025.